60 Degrees Pharmaceuticals (SXTP) to Release Quarterly Earnings on Thursday

60 Degrees Pharmaceuticals (NASDAQ:SXTP) is expected to release its Q3 2025 results before the market opens on Thursday, November 13th. Analysts expect the company to announce earnings of ($1.21) per share for the quarter. Investors can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Wednesday, November 19, 2025 at 12:30 PM ET.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.24) by ($0.01). The company had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.32 million. On average, analysts expect 60 Degrees Pharmaceuticals to post $-5 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

60 Degrees Pharmaceuticals Trading Down 0.8%

NASDAQ:SXTP opened at $1.27 on Wednesday. The firm has a market capitalization of $5.21 million, a PE ratio of -0.17 and a beta of 2.79. 60 Degrees Pharmaceuticals has a 1 year low of $1.18 and a 1 year high of $12.45. The firm’s fifty day simple moving average is $1.43 and its 200 day simple moving average is $1.80.

Analysts Set New Price Targets

A number of research firms have recently commented on SXTP. Ascendiant Capital Markets dropped their price objective on 60 Degrees Pharmaceuticals from $7.00 to $3.00 and set a “buy” rating on the stock in a research note on Wednesday, September 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, 60 Degrees Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $3.00.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.